Press Release Eikon Therapeutics Announces Dose Selection for TeLuRide-006, an Ongoing Adaptive Phase 2/3 Trial of EIK1001 in Advanced Melanoma 16 hours ago
Press Release Eikon Therapeutics Appoints Johnny Bennett, Ph.D. to its Scientific Advisory Board Aug 10
Press Release Eikon Therapeutics Announces First Patient Dosed in TeLuRide-008, a Registrational Phase 2/3 Trial of EIK1001 in Non-Small Cell Lung Cancer Jul 27